Breakthrough Gene Therapy Offers Long-Term Treatment for Genetic Vision Loss

A novel gene delivery vector targeting photoreceptor cells in the retina has yielded positive results in phase-two human trials. The treatment works by injecting corrected copies of the defective RPE65 gene directly into localized eye tissue. Over 80% of participants reported substantial improvements in night vision and color contrast within three weeks of therapy. Medical boards are evaluating the treatment for accelerated approvals.